Profile data is unavailable for this security.
About the company
Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.
- Revenue in JPY (TTM)494.71bn
- Net income in JPY51.40bn
- Incorporated1949
- Employees5.67k
- LocationKyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
- Phone+81 352057200
- Fax+81 352057182
- Websitehttps://www.kyowakirin.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tsumura & Co | 181.09bn | 32.43bn | 278.48bn | 4.27k | 8.49 | 0.9143 | 6.09 | 1.54 | 427.12 | 427.12 | 2,385.35 | 3,968.06 | 0.4058 | 0.72 | 2.73 | 42,390,680.00 | 7.74 | 5.53 | 9.75 | 6.85 | 50.02 | 49.39 | 19.06 | 14.50 | 2.62 | -- | 0.1766 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Hisamitsu Pharmaceutical Co Inc | 154.86bn | 19.53bn | 302.09bn | 2.80k | 15.06 | 1.09 | 11.37 | 1.95 | 266.82 | 266.82 | 2,114.93 | 3,703.39 | 0.4597 | 2.64 | 3.48 | 55,327,260.00 | 5.93 | 4.34 | 7.04 | 4.99 | 59.20 | 57.83 | 12.89 | 10.32 | 3.75 | -- | 0.0096 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Sumitomo Pharma Co Ltd | 398.83bn | 23.63bn | 425.75bn | 3.83k | 17.99 | 2.51 | 8.65 | 1.07 | 59.49 | 59.49 | 1,003.88 | 426.59 | 0.4834 | 1.46 | 5.96 | 104,079,300.00 | 2.86 | -5.49 | 5.29 | -8.49 | 61.53 | 67.88 | 5.93 | -13.24 | 0.6606 | 2.46 | 0.6496 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Rohto Pharmaceutical Co Ltd | 308.63bn | 31.01bn | 492.67bn | 9.14k | 15.39 | 1.81 | 11.17 | 1.60 | 135.51 | 135.51 | 1,349.22 | 1,151.04 | 0.8037 | 2.47 | 4.46 | 33,751,640.00 | 8.06 | 8.59 | 10.78 | 11.70 | 56.68 | 57.78 | 10.03 | 10.57 | 1.65 | -- | 0.1924 | 21.12 | 13.95 | 10.38 | 0.2263 | 15.01 | 10.42 | 22.59 |
| Santen Pharmaceutical Co Ltd | 300.00bn | 36.25bn | 579.28bn | 3.85k | 16.35 | 2.02 | 10.77 | 1.93 | 103.60 | 103.60 | 858.37 | 838.52 | 0.7101 | 2.72 | 3.88 | 77,943,360.00 | 8.49 | 3.94 | 10.75 | 4.93 | 57.01 | 58.97 | 11.95 | 6.01 | 1.99 | -- | 0.1072 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
| Ono Pharmaceutical Co Ltd | 486.87bn | 50.05bn | 810.13bn | 4.29k | 15.25 | 0.9753 | 10.51 | 1.66 | 106.52 | 106.52 | 1,036.36 | 1,665.60 | 0.4924 | 2.40 | 3.79 | 113,569,200.00 | 5.07 | 10.78 | 5.85 | 12.37 | 69.61 | 73.23 | 10.30 | 21.23 | 2.56 | 142.59 | 0.1569 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Eisai Co Ltd | 789.40bn | 46.43bn | 1.15tn | 13.51k | 24.05 | 1.32 | 13.06 | 1.46 | 163.81 | 163.81 | 2,784.17 | 2,982.52 | 0.5678 | 0.8644 | 4.47 | 58,448,100.00 | 3.46 | 3.81 | 4.68 | 5.14 | 78.62 | 77.46 | 6.09 | 6.44 | 1.37 | -- | 0.178 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Kyowa Kirin Co Ltd | 494.71bn | 51.40bn | 1.33tn | 5.67k | 26.05 | 1.60 | 17.38 | 2.69 | 97.34 | 97.34 | 939.97 | 1,588.59 | 0.4745 | 1.78 | 3.92 | 87,266,360.00 | 4.93 | 6.37 | 5.75 | 7.25 | 73.40 | 75.13 | 10.39 | 14.65 | 2.71 | 17.52 | 0.00 | 46.38 | 12.06 | 10.14 | -26.26 | 9.71 | 37.71 | 6.67 |
| Shionogi & Co Ltd | 438.27bn | 170.44bn | 2.24tn | 4.96k | 12.56 | 1.57 | 11.75 | 5.11 | 200.28 | 200.28 | 514.99 | 1,600.97 | 0.2969 | 0.979 | 3.61 | 88,449,650.00 | 11.49 | 12.17 | 12.69 | 13.74 | 85.44 | 84.91 | 38.68 | 38.30 | 6.13 | -- | 0.0158 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
| Astellas Pharma Inc | 1.91tn | 50.75bn | 2.63tn | 13.64k | 52.69 | 1.72 | 10.52 | 1.37 | 27.56 | 27.56 | 1,062.16 | 845.25 | 0.5536 | 1.28 | 3.28 | 140,168,800.00 | 1.47 | 3.05 | 2.22 | 4.45 | 81.74 | 81.15 | 2.65 | 5.42 | 0.8516 | 4.00 | 0.3824 | 131.42 | 19.25 | 8.01 | 197.72 | -23.64 | -5.94 | 13.09 |
| Otsuka Holdings Co Ltd | 2.39tn | 350.74bn | 3.62tn | 35.34k | 10.24 | 1.33 | 7.81 | 1.51 | 650.78 | 650.78 | 4,433.96 | 5,000.59 | 0.6701 | 2.29 | 5.03 | 67,722,650.00 | 9.92 | 5.91 | 12.38 | 7.27 | 72.20 | 69.18 | 14.81 | 9.89 | 1.44 | -- | 0.0859 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
Data as of Jul 18 2025. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY
12.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 03 Jul 2025 | 17.26m | 3.28% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 8.96m | 1.71% |
| Nikko Asset Management Co., Ltd.as of 04 Jul 2025 | 8.70m | 1.66% |
| Daiwa Asset Management Co. Ltd.as of 30 May 2025 | 7.94m | 1.51% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 5.81m | 1.11% |
| Goldman Sachs Asset Management Co., Ltd. (Japan)as of 30 Apr 2025 | 5.26m | 1.00% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 03 Jul 2025 | 4.58m | 0.87% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 3.75m | 0.71% |
| Geode Capital Management LLCas of 10 Jul 2025 | 2.61m | 0.50% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 2.25m | 0.43% |
More ▼
Data from 31 Dec 2024 - 30 Apr 2025Source: FactSet Research Systems Inc.
